Department of Pulmonary Medicine, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, the Netherlands.
J Heart Lung Transplant. 2022 Jun;41(6):765-772. doi: 10.1016/j.healun.2022.03.006. Epub 2022 Mar 16.
Serological responses to COVID-19 vaccination are diminished in recipients of solid organ transplants, especially in lung transplant recipients (LTR), probably as result of immunosuppressive treatment. There is currently no marker of immunosuppression that can be used to predict the COVID-19 vaccination response. Here, we study whether torque tenovirus (TTV), a highly prevalent virus can be used as an indicator of immunosuppression.
The humoral response to the mRNA 1273 vaccine was assessed in 103 LTR, who received a transplant between 4 and 237 months prior to vaccination, by measuring Spike (S)-specific IgG levels at baseline, 28 days after first, and 28 days after the second vaccination. TTV loads were determined by RT-PCR and Pearson's correlation coefficient was calculated to correlate serological responses to TTV load.
Humoral responses to COVID-19 vaccination were observed in 41 of 103 (40%) LTR at 28 days after the second vaccination. Sixty-two of 103 (60%) were non-responders. Lower TTV loads at baseline (significantly) correlated with higher S-specific antibodies and a higher percentage of responders. Lower TTV loads also strongly correlated with longer time since transplantation, indicating that participants with lower TTV loads were longer after transplantation.
This study shows a better humoral response to the SARS-CoV-2 vaccine in subjects with a lower TTV load pre-vaccination. In addition, TTV load correlates with the time after transplantation. Further studies on the use of TTV load in vaccination efficacy studies in immunocompromised cohorts should provide leads for the potential use of this marker for optimizing vaccination response.
COVID-19 疫苗接种后的血清学反应在实体器官移植受者中减弱,尤其是肺移植受者(LTR),可能是由于免疫抑制治疗。目前尚无可用于预测 COVID-19 疫苗接种反应的免疫抑制标志物。在这里,我们研究是否扭矩细小病毒(TTV),一种高度流行的病毒,可以用作免疫抑制的指标。
通过测量基线、第一次接种后 28 天和第二次接种后 28 天 S 特异性 IgG 水平,评估了 103 名 LTR 对 mRNA-1273 疫苗的体液反应,这些 LTR 在接种前 4 至 237 个月进行了移植。通过 RT-PCR 确定 TTV 载量,并计算 Pearson 相关系数以关联血清学反应与 TTV 载量。
在第二次接种后 28 天,103 名 LTR 中的 41 名(40%)观察到 COVID-19 疫苗接种的体液反应。103 名中的 62 名(60%)为无反应者。基线时较低的 TTV 载量(显著)与较高的 S 特异性抗体和较高的反应者百分比相关。较低的 TTV 载量也与移植后时间较长强烈相关,表明 TTV 载量较低的参与者移植时间较长。
这项研究表明,在接种前 TTV 载量较低的受试者中,对 SARS-CoV-2 疫苗的体液反应更好。此外,TTV 载量与移植后时间相关。进一步研究 TTV 载量在免疫功能低下队列疫苗接种效果研究中的应用,可为该标志物在优化疫苗接种反应中的潜在应用提供线索。